Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...
HS235 offers potential to treat pulmonary hypertension (PH) patients while reducing the risk of bleeding and providing unique metabolic benefits compared to existing therapies MONTREAL, Feb. 25, 2026 ...
Selected a potential first-in-class Pol Theta Helicase development candidate in collaboration with GSK Observed complete responses in preclinical combination studies of Pol Theta Helicase DC with ...
A major pharmaceutical company is leaving behind more than half a million square feet in a suburb of Washington, D.C. when its lease expires next year. London-based GSK is set to depart 635,000 square ...
GSK (LSE:GSK) has licensed worldwide rights to its experimental liver disease drug linerixibat to Alfasigma. The agreement ...
(Reuters) - Drugmaker GSK said Wednesday it would invest $30 billion in U.S. research and development and supply chain infrastructure over five years, after U.S. President Donald Trump arrived in ...
GSK Plc (NYSE:GSK) shelved on Wednesday its herpes simplex virus (HSV) vaccine development program. The recombinant protein vaccine, dubbed GSK3943104, did not meet the study’s primary efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results